La catena delle opzioni mostra i dati chiave delle opzioni azionarie di MoonLake a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per MoonLake..

MoonLake (NASDAQ:MLTX) Azioni, Catena delle Opzioni

MoonLake

MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake Immunotherapeutics

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and maintains $100 price target.

News

Price Target

Reiteration

Analyst Ratings

MLTX

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target

Biotech

General

MoonLake Immunotherapeutics Screens First Patients In Phase 3 IZAR Program

Wedbush analyst Yun Zhong assumes MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Outperform rating and lowers Price Target of $73.

Initiation

Wedbush Assumes MoonLake at Outperform, Lowers Price Target of $73

Cantor Fitzgerald analyst Prakhar Agrawal reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on MoonLake

Needham analyst Serge Belanger reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and maintains $62 price target.

Needham Reiterates Buy on MoonLake, Maintains $62 Price Target

Wolfe Research analyst Andy Chen downgrades MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) from Outperform to Peer Perform.

Downgrades

Wolfe Research Downgrades MoonLake to Peer Perform

Needham analyst Serge Belanger maintains MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and lowers the price target from $66 to $62.

Needham Maintains Buy on MoonLake, Lowers Price Target to $62

MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.28) by 39.29 percent.

Earnings

Earnings Misses

MoonLake Q2 2024 Adj EPS $(0.39) Misses $(0.28) Estimate

Oppenheimer analyst Andreas Argyrides initiates coverage on MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Outperform rating and announces Price Target of $104.

Oppenheimer Initiates Coverage On MoonLake with Outperform Rating, Announces Price Target of $104

Needham analyst Serge Belanger reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and maintains $66 price target.

Needham Reiterates Buy on MoonLake, Maintains $66 Price Target

MoonLake Immunotherapeutics Says FDA And EMA Both Unanimously Support Co.'s Proposed Approach For Advancing Its Phase 3 Program Of The Nanobody Sonelokimab In Psoriatic Arthritis

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody&#xAE; sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
<ul>
<li>VELA is the first Phase 3 program in hidradenitis suppurativa to use the higher clinical response level of HiSCR75 as the primary endpoint</li>
<li>The topline primary endpoint readout at week 16, together with data on other endpoints, is expected as of mid-2025
<ul>
<li>Program will evaluate sonelokimab for a total of 52 weeks, across VELA-1 and VELA-2, at sites in the United States and Europe, using a design informed by the landmark Phase 2 MIRA trial</li>
</ul>
</li>
</ul>

Moonlake Immunotherapeutics Begins Phase 3 VELA Program Of The Nanobody Sonelokimab In Patients With Moderate-To-Severe Hidradenitis Suppurativa; Topline Primary Endpoint Readout At Week 16, Together With Data On Other Endpoints, Is Expected As Of Mid-2025

Shares of Diodes Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIOD#NASDAQ">DIOD</a>) fell sharply during Friday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/DIOD/earnings">quarterly financial results</a>.
Diodes posted adjusted earnings of 28 cents per share, missing market estimates of 31 cents per share. The company's quarterly sales came in at $301.97 million missing expectations of $305.01 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Diodes shares dipped 9.8% to $68.99 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares jumped 139% to $10.73 after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and develop COVID-influenza combination vaccines.</li>
<li>iTeos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) gained 40% to $17.06 after the company announced a $120 million registered direct offering and reported Q1 financial results.</li>
<li>AEye, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIDR#NASDAQ">LIDR</a>) shares climbed 39.8% to $1.65 after the company disclosed a partnership with LITEON Technology Corporation.</li>
<li>Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) shares climbed 39.4% to $32.86 after the company reported better-than-expected first-quarter sales results.</li>
<li>Ouster, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) gained 34.3% to $13.90 after the company reported better-than-expected first-quarter financial results.</li>
<li>Organogenesis Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) rose 32% to $3.02 following upbeat quarterly results.</li>
<li>Inseego Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) gained 31.4% to $5.05 after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates.</li>
<li>CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) surged 26.3% to $13.99 after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Sensus Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) shares rose 22.5% to $4.6699 after the company reported better-than-expected first-quarter financial results.</li>
<li>Groupon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) gained 22.3% to $12.85 after the company reported better-than-expected first-quarter results.</li>
<li>Standard Lithium Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLI#NYSE">SLI</a>) jumped 21.8% to $1.90 after the company reported better-than-expected quarterly GAAP EPS results.</li>
<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) rose 21% to $8.39 after the company reported better-than-expected first-quarter financial results and issued strong revenue guidance.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) shares gained 19.3% to $5.66 in pre-market trading after the company reported better-than-expected first quarter financial results.</li>
<li>American Coastal Insurance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) rose 17.2% to $12.79 after the company reported better-than-expected first quarter financial results. The company announced the sale of 100% of its issued and outstanding stock of Interboro Insurance Company to Forza Insurance Holdings.</li>
<li>Global Gas Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HGAS#NASDAQ">HGAS</a>) rose 15.3% to $1.28.</li>
<li>Gen Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) gained 15% to $23.42 after the company reported better-than-expected quarterly earnings and authorized a $3 billion share repurchase program.</li>
<li>Mettler-Toledo International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>) gained 14.6% to $1,478.49 after the company reported better-than-expected first-quarter financial results and issued guidance.</li>
<li>SkyWater Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYT#NASDAQ">SKYT</a>) rose 14.4% to $7.61.</li>
<li>Clean Energy Fuels Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNE#NASDAQ">CLNE</a>) climbed 13.6% to $2.74 following upbeat quarterly results.</li>
<li>Natural Grocers by Vitamin Cottage, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGVC#NASDAQ">NGVC</a>) gained 13.2% to $20.19 following second-quarter results.</li>
<li>Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) rose 11.3% to $106.36 following strong first-quarter earnings.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) jumped 11% to $6.50 following first-quarter results.</li>
<li>Integral Ad Science Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) gained 8.8% to $9.12 after the company reported better-than-expected first-quarter sales results and issued FY24 revenue guidance above estimates.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) jumped 8.7% to $35.68 after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $33 to $46.</li>
<li>Funko Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) gained 7% to $7.30 as the company reported better-than-expected first-quarter earnings and issued strong earnings forecast for the second quarter. The company also appointed Cynthia Williams as its Chief Executive Officer, effective May 20.</li>
<li>Genpact Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) gained 6.8% to $34.26 after the company reported better-than-expected first-quarter financial results and raised its FY24 EPS range.</li>
<li>Array Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) shares rose 3.5% to $12.94 after the company reported stronger-than-expected financial results for the first quarter on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>MacroGenics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) shares fell 73.4% to $3.9089 after the company reported worse-than-expected first-quarter financial results.</li>
<li>Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) fell 37.2% to $0.0439 after jumping 20% on Thursday.</li>
<li>Flux Power Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLUX#NASDAQ">FLUX</a>) dipped 35.8% to $2.9350 after the company reported worse-than-expected quarterly financial results.</li>
<li>Antelope Enterprise Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) fell 29.3% to $1.30 after the company announced second half and full year 2023 financial results.</li>
<li>Evolv Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) fell 29.2% to $2.7290 after the company reported worse-than-expected first-quarter financial results and lowered its FY24 sales guidance below estimates.</li>
<li>Revance Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) fell 27% to $3.0950 as the company posted a loss for its first quarter on Thursday.</li>
<li>Biofrontera Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) fell 26.6% to $1.16.</li>
<li>American Vanguard Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVD#NYSE">AVD</a>) dipped 22.2% to $9.84 following weak quarterly results.</li>
<li>UTime Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) dipped 22% to $0.25.</li>
<li>The Beauty Health Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKIN#NASDAQ">SKIN</a>) fell 22% to $2.80 following quarterly results.</li>
<li>MicroVision, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) shares fell 21.6% to $1.27 after the company reported worse-than-expected first-quarter GAAP EPS results.</li>
<li>Progyny, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) shares fell 21.5% to $25.51 after the company reported worse-than-expected first-quarter sales results and issued FY24 sales guidance below estimates.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) shares declined 20.7% to $0.0579 after the company reported worse-than-expected first quarter financial results.</li>
<li>The E.W. Scripps Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSP#NASDAQ">SSP</a>) dipped 19.7% to $3.71 following quarterly results.</li>
<li>CS Disco, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAW#NYSE">LAW</a>) fell 19.6% to $6.50 following weak sales.</li>
<li>Safe and Green Development Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGD#NASDAQ">SGD</a>) shares fell 18.4% to $0.6937 after jumping around 37% on Thursday.</li>
<li>Docebo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) fell 18.2% to $37.99.</li>
<li>JFrog Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>) shares fell 17.7% to $33.43 after the company reported first quarter financial results.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) shares fell 17.3% to $0.7606 after the company reported worse-than-expected first-quarter sales results.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) fell 15.6% to $11.35 following first-quarter financial results.</li>
<li>Gritstone bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares declined 14.4% to $0.8320 after the company reported worse-than-expected first quarter GAAP EPS results.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) shares fell 12.8% to $4.0850 after the company reported worse-than-expected first-quarter adjusted EPS results.</li>
<li>Forward Air Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) declined 12.2% to $14.72.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) fell 11.1% to $21.97 after the company reported second-quarter financial results.</li>
<li>AMN Healthcare Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>) fell 9.5% to $55.08 following first-quarter results.</li>
<li>Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) fell 8.4% to $24.69 after the company reported first-quarter financial results.</li>
<li>Akamai Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) fell 8.1% to $94.16 after the company issued weak guidance.</li>
<li>Fluence Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) declined 7.8% to $17.28 following second-quarter financial results.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) dipped 7.4% to $3.3399.</li>
<li>MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) fell 7% to $39.02.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) fell 5% to $33.13. BMO Capital analyst James Fotheringham maintained Affirm with a Market Perform and lowered the price target from $48 to $46.</li>
<li>Runway Growth Finance Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RWAY#NASDAQ">RWAY</a>) shares fell 4.1% to $11.61 as the company priced its secondary offering of 3.75 million common stock by selling stockholder at $11.50 per share.</li>
<li>Yelp Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>) shares declined 3.6% to $38.20 after the company reported a first-quarter revenue miss.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38760794/bitcoin-tops-63-000-akash-network-emerges-as-top-gainer">Bitcoin Tops $63,000; Akash Network Emerges As Top Gainer</a>

Intraday Update

Movers

ACIC

ADMA

AEHL

AFRM

AKAM

ARRY

ARWR

BFRI

BROS

CDNA

CLNE

DCBO

DIOD

EVLV

FLNC

FLUX

FNKO

FROG

FWRD

GRPN

GRTS

GWAV

HGAS

INSG

IOVA

ITOS

LIDR

MGNX

MVIS

NGVC

NTRA

NVAX

NVTS

ORGO

OUST

PEGY

PGNY

RVNC

RWAY

SKIN

SKYT

SOUN

SRTS

YELP

Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

In a report released today, Yun Zhong from Wedbush reiterated a Buy rating on MoonLake Immunotherapeutics (MLTX – Research Report), with a price ta...

MoonLake Immunotherapeutics: Strategic Growth and Financial Stability Drive Buy Rating

TD Cowen analyst Phil Nadeau has maintained their bullish stance on MLTX stock, giving a Buy rating today. Phil Nadeau's rating is based on several...

Promising Growth Prospects for MoonLake Immunotherapeutics: Buy Rating Supported by Strategic Developments in HS and PsA Programs

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on MoonLake Immunotherapeutics (MLTX – Research Report). The associated p...

MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Trials Support 'Buy' Rating

Needham analyst Serge Belanger maintained a Buy rating on MoonLake Immunotherapeutics (MLTX – Research Report) today and set a price target of $62....

Strategic Initiatives and Financial Stability Propel MoonLake Immunotherapeutics Towards Promising Market Position

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Molina Healthcare (MOH – Research Report), Avidity...

Analysts Conflicted on These Healthcare Names: Molina Healthcare (MOH), Avidity Biosciences (RNA) and MoonLake Immunotherapeutics (MLTX)

Moonlake Immunotherapeutics ( ($MLTX) ) has released its Q3 earnings. Here is a breakdown of the information Moonlake Immunotherapeutics presented ...

MoonLake Immunotherapeutics Reports Q3 2024 Financial Results

Analyst Thomas Smith of Leerink Partners reiterated a Buy rating on MoonLake Immunotherapeutics (MLTX – Research Report), retaining the price targe...

Buy Rating for MoonLake Immunotherapeutics Driven by Clinical Advancements and Market Opportunities

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on MoonLake Immunotherapeutics (MLTX – Research Report). The associated p...

Buy Rating for MoonLake Immunotherapeutics Driven by Promising Clinical Advancements and Strong Market Potential

MoonLake Immunotherapeutics (MLTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Juli...

Promising Outlook for MoonLake's Sonelokimab in Psoriatic Arthritis Treatment

In a report released today, Yun Zhong from Wedbush maintained a Buy rating on MoonLake Immunotherapeutics (MLTX – Research Report), with a price ta...

MoonLake Immunotherapeutics' Promising Phase 3 Trials for PsA Treatment Drives Buy Rating

Press Releases

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

Comments

MoonLake

MoonLake (MLTX) Opzioni

MoonLake (NASDAQ:MLTX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO